Hennessy Advisors Inc. Boosts Holdings in DaVita Inc. (NYSE:DVA)

Hennessy Advisors Inc. raised its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 6.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,300 shares of the company's stock after buying an additional 4,700 shares during the period. Hennessy Advisors Inc. owned about 0.09% of DaVita worth $10,962,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after acquiring an additional 92,014 shares during the period. KBC Group NV lifted its position in shares of DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company's stock worth $51,395,000 after purchasing an additional 67,250 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of DaVita by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company's stock worth $47,874,000 after purchasing an additional 56,389 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock worth $39,712,000 after buying an additional 12,339 shares during the last quarter. Finally, abrdn plc raised its stake in shares of DaVita by 1.2% during the third quarter. abrdn plc now owns 189,065 shares of the company's stock worth $30,719,000 after buying an additional 2,180 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Up 0.9 %

DVA traded up $1.43 during trading on Friday, hitting $166.28. 429,777 shares of the company's stock were exchanged, compared to its average volume of 606,593. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The business's 50 day moving average is $157.11 and its two-hundred day moving average is $152.71. DaVita Inc. has a fifty-two week low of $103.40 and a fifty-two week high of $169.51. The stock has a market cap of $13.63 billion, a P/E ratio of 17.94, a PEG ratio of 0.75 and a beta of 0.92.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the previous year, the company posted $2.85 EPS. DaVita's quarterly revenue was up 4.6% compared to the same quarter last year. As a group, equities analysts expect that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on DVA. Barclays increased their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Truist Financial lifted their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, DaVita has a consensus rating of "Hold" and a consensus target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.